<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04522297</url>
  </required_header>
  <id_info>
    <org_study_id>02-2018</org_study_id>
    <nct_id>NCT04522297</nct_id>
  </id_info>
  <brief_title>Nor-epinephrine Versus Midodrine/Octreotide in Patients With Hepatorenal Syndrome</brief_title>
  <official_title>Nor-epinephrine Versus Midodrine/Octreotide in Patients With Hepatorenal Acute Kidney Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Hepatology &amp; Tropical Medicine Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Hepatology &amp; Tropical Medicine Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatorenal syndrome is a functional renal impairment occurring in cirrhotic patients . It&#xD;
      develops secondary to splanchnic arterial vasodilatation which decreases the effective blood&#xD;
      volume, activate the renin-angiotensin-aldosterone system, and stimulate of sympathetic&#xD;
      nervous system.This study aims to compare the efficacy of nor-epinephrine versus midodrine/&#xD;
      octreotide, together with intravenous albumin on renal functions of patients with hepatorenal&#xD;
      acute kidney injury.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 15, 2018</start_date>
  <completion_date type="Actual">January 23, 2020</completion_date>
  <primary_completion_date type="Actual">January 23, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Full response</measure>
    <time_frame>10 days</time_frame>
    <description>the proportion of patients achieved full response defined as return of serum creatinine to a value within 0.3 mg/dl of the baseline value</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Partial response</measure>
    <time_frame>10 days</time_frame>
    <description>defined as a regression of at least one acute kidney injury stage with a fall in the serum creatinine value to ≥0.3 mg/dl above the baseline serum creatinine value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reversal</measure>
    <time_frame>10 days</time_frame>
    <description>Incidence of HRS reversal defined as at least one serum creatinine value of ≤ 1.5 mg/dl while on treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Hepato-Renal Syndrome</condition>
  <arm_group>
    <arm_group_label>Midodrine/Octreotide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral midodrine plus octreotide as subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nor-epinephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous infusion norepinephrine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midodrine/Octreotide</intervention_name>
    <description>oral midodrine plus octreotide as subcutaneous injection</description>
    <arm_group_label>Midodrine/Octreotide</arm_group_label>
    <other_name>albumin at doses of 20 to 40 g/day</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nor-epinephrine</intervention_name>
    <description>Intravenous infusion norepinephrine</description>
    <arm_group_label>Nor-epinephrine</arm_group_label>
    <other_name>albumin at doses of 20 to 40 g/day</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Both sexes aged 18 years or older having cirrhosis, ascites, and a diagnosis of HRS-AKI&#xD;
        based on the 2015 International Club of Ascites (ICA) diagnostic criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Serum creatinine (sCr) &gt;7 mg/dL Hypotension (mean arterial pressure (MAP) &lt;70 mm Hg) or&#xD;
        sepsis. Recent treatment with vasopressors. Patients with severe cardiovascular disease&#xD;
        Known allergy to study medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doaa Abdelaziz yousef, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Fellow at The National Hepatology and Tropical Research medicine institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The National Hepatology and Tropical Research medicine institute</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>August 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2020</study_first_posted>
  <last_update_submitted>August 18, 2020</last_update_submitted>
  <last_update_submitted_qc>August 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Hepatology &amp; Tropical Medicine Research Institute</investigator_affiliation>
    <investigator_full_name>Doaa abdelaziz</investigator_full_name>
    <investigator_title>Lecturer of clinical pharmacy</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatorenal Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octreotide</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Midodrine</mesh_term>
    <mesh_term>Norepinephrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

